Business Context and Reporting Period
Alector, Inc. (ALEC) is a biotechnology company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, utilizing its proprietary Alector Brain Carrier (ABC) platform. This summary covers the quarterly period ended June 30, 2026.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Collaboration Revenue | $3.3 million | $7.9 million | $4.4 million | $11.5 million |
| Net Loss | $(23.0) million | $(30.5) million | $(45.9) million | $(71.0) million |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.30) | $(0.41) | $(0.71) |
| Cash, Cash Equivalents, and Marketable Securities | $172.8 million (as of June 30, 2026) | N/A | ||
| Accumulated Deficit | $(1,018.0) million | N/A | ||
| Deferred Revenue (GSK Agreement) | $162.9 million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by 58% year-over-year for the quarter and 62% year-over-year for the six-month period. This reduction is primarily attributed to lower revenue recognition for the AL101 (nivisnebart) Alzheimer's disease program following the discontinuation of the Phase 2 PROGRESS-AD trial in April 2026 due to futility.
- Expense Reduction: Total operating expenses decreased by 34% for the quarter and 41% year-over-year for the six-month period. This was driven by significant workforce reductions (approximately 47% of the workforce in October 2025) and the wind-down of clinical trials for latozinemab and nivisnebart.
- Improved Loss Profile: Net loss narrowed by 25% for the quarter and 35% for the six-month period compared to the prior year, reflecting the successful cost-cutting measures.
- Debt Repayment: In a subsequent event on July 8, 2026, the Company repaid in full a $10.4 million loan agreement with Hercules Capital, Inc., eliminating this debt obligation.
Guidance, Outlook, and Risks
- Liquidity and Runway: As of June 30, 2026, the Company held $172.8 million in cash, cash equivalents, and marketable securities. Management anticipates this provides a runway to fund operations at least through 2027.
- Collaboration Termination: On July 6, 2026, GSK provided written notice terminating the Collaboration and License Agreement effective January 2, 2027. This follows the discontinuation of development for latozinemab and nivisnebart. Consequently, Alector will not receive up to $1.5 billion in potential milestone payments or royalties under this agreement.
- Pipeline Focus: The Company is pivoting to its wholly owned pipeline built on the ABC platform. Key programs include:
- AL137: Anti-amyloid beta antibody for Alzheimer's disease; IND submission targeted for Q1 2027.
- AL064/AL164: Tau siRNA program for Alzheimer's and tauopathies.
- AL050: GCase enzyme replacement therapy for Parkinson's disease.
- Risks: Significant risks include the high uncertainty of drug development, the need for substantial additional financing, and the impact of the GSK termination on future revenue streams. The Company has no approved products and expects to incur net losses for the foreseeable future.
Investor Verification Checklist
- Verify the sufficiency of the $172.8 million cash balance to fund operations through 2027 given the loss of GSK collaboration revenue.
- Confirm the timeline and regulatory status of the AL137 IND submission targeted for Q1 2027.
- Review the specific terms of the GSK termination notice and any potential remaining obligations or liabilities.
- Assess the impact of the recent 47% workforce reduction on the Company's ability to execute its new pipeline strategy.
- Monitor the status of the new at-the-market (ATM) sales agreement entered into in May 2026 for potential future capital raises.